Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome

Clinical and Diagnostic Laboratory Immunology

Volumn 3, Issue 2, 1996, Pages 175-183

  Stove S ^a   Welte, T ^a,b   Wagner, T O F ^a   Kola, A ^a   Klos, A ^a   Bautsch, W ^a   Kohl J ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY DISTRESS SYNDROME; SEPSIS;

EID: 0029958832     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.3.2.175-183.1996     Document Type: Article

References (20)

1. Barton, P. A., and J. S. Warren. 1993. Complement component C5 modulates the systemic tumor necrosis factor response in murine endotoxic shock. Infect. Immun. 61:1474-1481.
2. Bengtson, A., and M. Heideman. 1988. Anaphylatoxin formation in sepsis. Arch. Surg. 123:545-649.
3. Beutler, B., I. W. Milsark, and A. C. Cerami. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871.
4. Bhakdi, S., W. Fassbender, F. Hugo, M.-P. Carreno, C. Berstecher, P. Malasit, and M. D. Kazatchkine. 1988. Relative inefficiency of terminal complement activation. J. Immunol. 141:3117-3122.
5. Björk, J., T. E. Hugli, and G. Smedegard. 1985. Microvascular effects of anaphylatoxins C3a and C5a. J. Immunol. 134:1115-1119.
6. Bone, R. C., R. A. Balk, F. B. Cerra, R. P. Dellinger, A. M. Fein, W. A. Knaus, R. M. H. Schein, and W. J. Sibbald. 1992. ACCP/SCCM consensus conference: definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1644-1655.
7. Cochrane, C. G., and H. J. Müller-Eberhard. 1968. The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J. Exp. Med. 127:371-386.
8. Duchateau, J., M. Haas, H. Schreyen, L. Radoux, I. Sprangers, F. X. Noel, M. Braun, and M. Lamy. 1984. Complement activation in patients at risk of developing the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 130:1058-1064.
9. Ember, J. A., S. D. Sanderson, T. E. Hugli, and E. L. Morgan. 1994. Induction of interleukin-8 synthesis from monocytes by human C5a anaphylatoxin. Am. J. Pathol. 144:393-403.
10. Fearon, D. T., S. Ruddy, P. H. Schur, and W. R. McCabe. 1975. Activation of the properdin pathway of complement in patients with gram-negative bacteremia. N. Engl. J. Med. 292:937-940.
11. Fernandez, H. N., P. M. Henson, A. Otani, and T. E. Hugli. 1978. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J. Immunol. 120:109-115.
12. Gardinali, M., P. Padalino, S. Vesconi, A. Calcagno, S. Ciappellano, L. Conciato, O. Chiara, A. Agostoni, and A. Nespoli. 1992. Complement activation and polymorphonuclear neutrophil leukocyte elastase in sepsis. Correlation with severity of disease. Arch. Surg. 127:1219-1224.
13. Goldstein, I. M. 1988. Complement: biologically active products, p. 55-74. In J. I. Gallin, I. M. Goldstein, and R. Snyderman (ed.), Inflammation: basic principles and clinical correlates. Raven Press, Ltd., New York.
14. Goldstein, I. M., and G. Weissmann. 1974. Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J. Immunol. 113:1583-1588.
15. Hack, C. E., J. H. Nuijens, R. J. Felt Bersma, W. O. Schreuder, A. J. Eerenberg Belmer, J. Paardekooper, W. Bronsveld, and L. G. Thijs. 1989. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am. J. Med. 86:20-26.
16. Haeffner-Cavaillon, N., J. M. Cavaillon, M. Laude, and M. D. Kazatchkine. 1987. C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. J. Immunol. 139:794-799.
17. Hartmann, H., B. Lübbers, M. Casaretto, W. Bautsch, A. Klos, and J. Köhl. 1993. Rapid quantification of C3a and C5a using a combination of chromatographic and immunoassay procedures. J. Immunol. Methods 166:35-44.
18. Haviland, D. L., R. L. McCoy, W. T. Whitehead, H. Akama, E. P. Molmenti, A. Brown, J. C. Haviland, W. C. Parks, D. H. Perlmutter, and R. A. Wetsel. 1995. Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J. Immunol. 154:1861-1869.
19. Heideman, M., and T. E. Hugli. 1984. Anaphylatoxin generation in multisystem organ failure. J. Trauma 24:1038-1043.
20. Heideman, M., B. Norder-Hansson, A. Bengtson, and T. E. Mollnes. 1988. Terminal complement complexes and anaphylatoxins in septic and ischemic patients. Arch. Surg. 123:188-192.